Patient engagement a resource-intense but de-risking exercise, says NDA Group

By Flora Southey

- Last updated on GMT

(Image: Getty/JanPietruszka)
(Image: Getty/JanPietruszka)

Related tags Patient centricity Data Drug development

Engaging with patients in the early stages of drug development is a ‘de-risking’ approach to regulatory approval, says consultant.

According to NDA Group scientific director, Markku Toivonen, patient engagement – which covers patient-centric approaches to pharmaceutical R&D and patient-derived outcomes – is attracting increased attention in the drug development landscape.

“Patient engagement is everywhere. It has been adopted by both big pharma and smaller companies,” ​Toivonen told delegates at Nordic Life Science Days last month.

And while implementing patient-centric strategies throughout the development stage can cost time, money and planning, according to Toivonen, it ‘pays off’ in the long-term.

“It is a de-risking exercise, particularly in rare conditions where…clinical data will help you understand which patient-reported outcomes should be taken to confirmatory trials,” ​he said, adding that understanding the clinical relevance of a treatment’s effect can be one of the “main stumbling blocks” ​for new drug applications.

“If you have relevant endpoints measuring…the subject’s benefits, you are much better off.”

Looking ahead

According to Toivonen, in the future, patient-reported outcomes – designed to reflect benefits truly perceived by patients – will carry more weight in regulatory reviews and “take a major role in health technology assessment”.

However, pharmaceutical companies must take responsibility, and act now, he told delegates. “I want to emphasise: Do not leave patient engagement only to the regulators…or their public advisory boards.”

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers